Treatment
Enasidenib clinical trials
We’re tracking 12 recruiting studies that include Enasidenib, each written for real people, not researchers, below.
Recruiting studies
- NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Berkeley, CaliforniaAges 18 years+ - NCT06240754RecruitingPhase 2
Study of enasidenib for low blood counts with IDH2 mutation
This trial tests a drug called enasidenib for people who have had low blood counts for at least 6 months and have a specific mutation in the IDH2 gene. The study aims to see if the drug can improve blood counts and is done mostly from home with fewer clinic visits.
St Louis, MissouriAges 18 years+ - NCT03383575RecruitingPhase 2
Azacitidine plus enasidenib for IDH2-mutant MDS
This trial tests whether combining azacitidine with enasidenib helps people with myelodysplastic syndrome (MDS) that has an IDH2 mutation. It’s designed for people who are either new to “hypomethylating” treatment or whose MDS returned/worsened after it.
Baltimore, MarylandAges 12 years+ - NCT03683433RecruitingPhase 2
Enasidenib plus azacitidine for IDH2-mutated AML
This trial studies the combination of enasidenib and azacitidine in people with acute myeloid leukemia (AML) that has an IDH2 gene mutation. It may help control the leukemia when prior treatments didn’t work or the disease came back.
Houston, TexasAges 18 years+ - NCT04774393RecruitingPhase 1/Phase 2
Study for AML after it returns or resists treatment
This Phase 1/2 trial tests a combination of medicines (decitabine/cedazuridine, venetoclax, and ivosidenib or enasidenib) in people with acute myeloid leukemia (AML) that has come back or hasn’t responded. It may help control the leukemia by targeting cancer cells and specific genetic changes in the leukemia.
Houston, TexasAges 18 years+ - NCT05010772RecruitingPhase 1
Maintenance treatment study for AML in remission
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT05756777RecruitingPhase 1
Gilteritinib plus other IDH medicine for relapsed AML
This Phase 1 study tests how well gilteritinib works when combined with either ivosidenib or enasidenib in adults with relapsed or refractory acute myeloid leukemia (AML). It targets specific genetic changes in the leukemia and may help shrink or control the cancer when standard options haven’t worked.
Basking Ridge, New JerseyAges 18 years+ - NCT06176989RecruitingPhase 2
Enasidenib for IDH2-mutated sinonasal and skull base tumors
This trial tests an oral targeted therapy called enasidenib for people with rare head and neck cancers that have an IDH2 gene mutation. The goal is to see if this drug can shrink or slow the growth of these tumors.
Bethesda, MarylandAges 18–120 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Birmingham, AlabamaAges 18 years+ - NCT05401097RecruitingPhase 2
Venetoclax plus IDH-targeted pills for AML patients who can’t get intensive chemo
This Phase 2 trial tests different ways of using medicines that target IDH mutations (IDH-targeted treatment) plus venetoclax in people newly diagnosed with IDH-mutated AML. It’s designed for patients who cannot safely receive intensive induction chemotherapy, to see which approach works best and is tolerable.
Aurora, ColoradoAges 18 years+ - NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years
What Enasidenib is being studied for
Conditions with recruiting Enasidenib studies.
- Acute Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Pediatric Cancer
- Myelodysplastic Syndrome With Excess Blasts
- Recurrent High Risk Myelodysplastic Syndrome
- Refractory High Risk Myelodysplastic Syndrome
- Acute Biphenotypic Leukemia
- Acute Myeloid Leukemia Post Cytotoxic Therapy
Common questions
- Are there clinical trials studying Enasidenib?
- Yes. Clin2 currently lists 12 recruiting studies that include Enasidenib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Enasidenib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Enasidenib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Enasidenib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.